AC Immune SA designs and develops vaccines, antibodies, small molecules, and diagnostic products for the treatment and prevention of neurodegenerative diseases with protein misfolding. Its platforms generate selective medical applications that interact with misfolded proteins in the brain. AC Immune SA has multiple drug candidates in clinical studies for Alzheimer’s disease, Down syndrome, and for Tau-PET imaging tracer.